GSK-3β-regulated N-acetyltransferase 10 Is Involved in Colorectal Cancer Invasion.
By: Hong Zhang, Wei Hou, Hua-Li Wang, Hai-Jing Liu, Xin-Ying Jia, Xingzheng Zheng, Yong-Xin Zou, Xin Li, Lin Hou, Michael A McNutt, Bo Zhang

Department of Pathology, Peking University Health Science Center.
2014-7-2; doi: 10.1158/1078-0432.CCR-13-3477
Abstract

Purpose: NAT10 (N-acetyltransferase 10) is a nucleolar protein, but may show subcellular redistribution in colorectal carcinoma (CRC). In this study, we evaluated membranous staining of NAT10 in colorectal carcinoma and its clinical implications, and explored the mechanism of regulation of NAT10 redistribution. Experimental Design: The expression and subcellular redistribution of NAT10, β-catenin, E-cadherin, GSK-3β were evaluated by immunohistochemistry in 222 cases of colorectal carcinoma. Regulation of NAT10 and its influence on cell motility were analyzed with inhibitors of GSK-3β, transfection of wild-type or kinase-inactivated GSK-3β, or expression of various domains of NAT10, and evaluated with immunofluorescence, Western blotting, and Trans-well assays. Results: NAT10 localized mainly in the nucleoli of normal tissues, and was redistributed to the membrane in cancer cells, particularly at the invasive "leading edge" of the tumor. This correlated well with nuclear accumulation of β-catenin (p<0.001). In addition, NAT10 membrane staining reflected depth of invasion and tendency to metastasize (all P values <0.001), and was associated with poorer prognosis (P=0.023). Evaluation of the mechanism involved demonstrated that subcellular redistribution of NAT10 may result from its increased stability and nuclear export, which is brought about by inhibition of GSK-3β. Moreover, redistribution of NAT10 induces alteration of cytoskeletal dynamics and increases cancer cell motility. Conclusions: The subcellular redistribution of NAT10 can be induced by decreases in GSK-3β activity. This redistribution increases cancer cell motility, and is thus correlated with invasive potential and poorer clinical outcome. This suggests NAT10 may be a useful prognostic marker and potential therapeutic target in CRC.



Copyright © 2014, American Association for Cancer Research.

PMID:24982245






Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements